Expert Interview
Examining Sage Therapeutic's SAGE-718 in patients with mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease and its recent Phase 2 LUMINARY trial results presented at AAN
Ticker(s): SAGEInstitution: Zucker Hillside Hospital
- Chief of Neurology at Zucker Hillside Hospital
- Professor of neurology and psychiatry at Donald and Barbara Zucker School of Medicine
- Manages 150 patients with Alzheimer's Disease
- Has been a Principal Investigator in clinical research studies of Alzheimer’s disease, mild cognitive impairment, and vascular dementia.
Roughly how many patients do you currently manage with Alzheimer's disease
Added By: dami_adminOn a scale from 1 -10 (10 being extremely excited) where would you rate your level of excitement for SAGE-718?
Added By: dami_adminWhat is the current standard of care in patients with MCI and mild dementia due to Alzheimer's?
Added By: dami_adminWhat current treatment options are the most utilized by physicians?
Added By: dami_adminSAGE-718 is an oral drug designed to modulate NMDA receptor activity.
Can you talk about the role of NMDA activity in Alzheimer's and whether you think this mechanism of action to increase its activity through a positive allosteric modulator like SAGE-718 has promise for Alzheimer's disease?
Could you please discuss with us about the recent results of the executive performance tests and the improvement on key tests of learning and memory in the LUMINARY Study? How does it compare to standard of care?
What’s your impression on the results for the Montreal Cognitive Assessment (MoCA) (+2.3 points vs baseline) observed at Day 28. At baseline, the average was 20.7 with Std deviation of 2.6 points. Would a 2.3 magnitude of change be clinically meaningful?
How does the lack of effect observed on measures of simple attention/psychomotor speed add context to this if any?
How relevant are the tests the company performed, namely the Digit Symbol Substitution, Multitasking, One Touch Stockings, Spatial Working Memory, and 2-Back tests) and learning and memory (Pattern Recognition Memory and Verbal Recognition Memory tests). Are there any other results you’d expect to see in an Alzheimer’s Dementia trial?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
